Zhejiang Xianju Pharmaceutical Co Ltd (002332) — Cash Flow Reinvestment Rate
Zhejiang Xianju Pharmaceutical Co Ltd (002332) has a Cash Flow Reinvestment Rate of 0.23x as of September 2025, reinvesting CN¥30.01 Million (capex CN¥30.01 Million ) from operating cash flow of CN¥130.05 Million. Check Zhejiang Xianju Pharmaceutical Co Ltd (002332) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Zhejiang Xianju Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2006–2025)
Historical reinvestment intensity for Zhejiang Xianju Pharmaceutical Co Ltd across 20 annual periods. Explore Zhejiang Xianju Pharmaceutical Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Zhejiang Xianju Pharmaceutical Co Ltd (2006–2025)
Year-by-year capital reinvestment analysis for Zhejiang Xianju Pharmaceutical Co Ltd. For live market cap and broader valuation context, see how much is Zhejiang Xianju Pharmaceutical Co Ltd worth.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.85x | CN¥210.78 Million | CN¥247.48 Million | CN¥209.07 Million | ▲ +49.1% |
| 2024 | 0.57x | CN¥227.68 Million | CN¥398.66 Million | CN¥207.59 Million | ▼ -21.1% |
| 2023 | 0.72x | CN¥431.26 Million | CN¥595.48 Million | CN¥234.63 Million | ▼ -31.1% |
| 2022 | 1.05x | CN¥640.61 Million | CN¥609.28 Million | CN¥282.54 Million | ▲ +160.0% |
| 2021 | 0.40x | CN¥273.38 Million | CN¥676.15 Million | CN¥266.84 Million | ▼ -46.5% |
| 2020 | 0.76x | CN¥596.55 Million | CN¥789.23 Million | CN¥118.17 Million | ▲ +32.7% |
| 2019 | 0.57x | CN¥296.18 Million | CN¥519.81 Million | CN¥262.34 Million | ▼ -61.7% |
| 2018 | 1.49x | CN¥287.70 Million | CN¥193.27 Million | CN¥169.26 Million | ▼ -1.5% |
| 2017 | 1.51x | CN¥253.16 Million | CN¥167.47 Million | CN¥123.28 Million | ▲ +77.1% |
| 2016 | 0.85x | CN¥133.11 Million | CN¥155.91 Million | CN¥97.10 Million | ▼ -65.9% |
| 2015 | 2.50x | CN¥499.17 Million | CN¥199.61 Million | CN¥115.05 Million | ▲ +227.2% |
| 2014 | 0.76x | CN¥108.26 Million | CN¥141.64 Million | CN¥108.26 Million | ▼ -74.4% |
| 2013 | 2.98x | CN¥189.26 Million | CN¥63.46 Million | CN¥189.26 Million | ▼ -66.5% |
| 2012 | 8.91x | CN¥298.01 Million | CN¥33.43 Million | CN¥298.01 Million | ▲ +380.1% |
| 2011 | 1.86x | CN¥274.14 Million | CN¥147.63 Million | CN¥274.14 Million | ▲ +360.8% |
| 2010 | 0.40x | CN¥62.58 Million | CN¥155.29 Million | CN¥62.58 Million | ▼ -1.8% |
| 2009 | 0.41x | CN¥42.94 Million | CN¥104.68 Million | CN¥42.94 Million | ▼ -75.1% |
| 2008 | 1.64x | CN¥59.25 Million | CN¥36.03 Million | CN¥59.25 Million | ▲ +135.0% |
| 2007 | 0.70x | CN¥67.55 Million | CN¥96.53 Million | CN¥67.55 Million | ▲ +1.7% |
| 2006 | 0.69x | CN¥36.51 Million | CN¥53.05 Million | CN¥36.51 Million | — |